The medicinal landscape in this country is increasingly characterized by a pattern toward market consolidation, with a handful of prominent companies wielding significant power. These sector giants, often bolstered by long-standing distribution networks and robust brand recognition, present a difficult picture for competition and affordable healthc

The Indian pharmaceutical industry, known for its affordable and accessible medicines, faces increasing concerns about monopolies. A few dominant companies control a significant share of the market, potentially limiting competition and driving up prices for consumers. This concern raises doubts about the long-term impact on patient access to affor